TLR-AD1
Glioblastoma Multiforme (GBM)
Pre-INDIND filing stage; Orphan Drug Designation granted
Key Facts
Indication
Glioblastoma Multiforme (GBM)
Phase
Pre-IND
Status
IND filing stage; Orphan Drug Designation granted
Company
About NovAccess Global
NovAccess Global Inc. is a biotechnology company with a dual-pronged strategy: developing its lead asset, TLR-AD1, a personalized dendritic cell therapy for glioblastoma, and building a data-centric platform leveraging AI and blockchain for therapeutic discovery. Key achievements include securing Orphan Drug Designation from the FDA for TLR-AD1 and uplisting to the OTCQB Venture Market. The company's mission is to leverage its patented TLR-AD1 platform and AI-driven analytics to create novel, ultra-targeted immunotherapies that enhance a patient's own immune system to fight cancer.
View full company profileOther Glioblastoma Multiforme (GBM) Drugs
| Drug | Company | Phase |
|---|---|---|
| GCT-007 | Global Cancer Technology | Pre-clinical |
| Tinostamustine | Imbrium Therapeutics | Phase 2 |
| Dendritic Cell Vaccine | Mill Creek Life Sciences | Pre-clinical |
| CYNK-GDT | Celularity | Preclinical |